Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Challenges With ICD Leads Are Under Control, St. Jude Tells Investors

This article was originally published in The Gray Sheet

Executive Summary

The company was prepared for FDA’s recent warning letter, executives said on an earnings call. But the scrutiny is not over, analysts suggest.


Related Content

Regulatory Roundup: St. Jude Resolves Warning Letter; Classifications; IMDRF
St. Jude Warning Letter Updates: CRM Facility Reinspected; Neuro Plant Awaits FDA Visit
St. Jude Announces CRM Approvals, Progress With Warning Letter
St Jude Begins Major Lead Assessment Study
Medtronic Emphasizes International Growth Opportunities
Medtronic Emphasizes International Growth Opportunities
Boston Scientific Continues Worldwide Restructuring, Plans Job Cuts
St. Jude Warning Letter Adds More Pressure On Firm’s Leads Division
St. Jude Confident In 2013 Growth Plan Despite Market Challenges
St. Jude Tries To Get Ahead Of Questions On Durata ICD Leads


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts